Esophageal adenocarcinoma · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin, Irinotecan, RT Variant #01 | — | R 2 267 | 35d | — | — | — | — | — |
Cisplatin and Fluorouracil (CF) and RT Variant #13 | — | R 1 850 | 28d | — | 16.0 mo | — | — | — |
Fluorouracil, Paclitaxel, RT Variant #01 | — | R 1 767 | 35d | — | — | — | — | — |
Cisplatin and Paclitaxel (TP) and RT N/A - secondary systemic drug | — | R 350 | 28d | — | — | — | — | 1 |
Cisplatin, Etoposide, RT Partial | — | — | — | — | — | — | — | — |
5 of 5 regimens shown